Subsequently, Iuliia Efimova and her colleagues suggested that when early ferroptotic cancer cells (specifically MCA205 cells) are taken up by BMDCs, they can trigger the activation of BMDCs by inducing the expression of CD80, CD86, and MHCII on BMDCs, potentially serving as a cancer treatment vaccine. The gene discussed is CD86; the disease is cancer.